Related Experiment Videos
[Assessment of coronary revascularization with 99mTC-sestamibi SPECT. Quantitative analysis of segmentary perfusion]
T Massardo Vega1, M J Jofré Manieu, A Muñoz Meynet
1Centro de Medicina Nuclear, Hospital Clínico Universidad de Chile, Santiago, 6531063, Chile. tmassardo@ns.hospital.uchile.cl
Insights
Revascularization moderately improved myocardial perfusion defects and significantly reduced ischemia in patients with myocardial infarction. This study assessed changes using Dipyridamole-99mTc-Sestamibi SPECT imaging.
Area of Science:
- Cardiology
- Nuclear Medicine
- Radiology
Background:
- Myocardial perfusion defects are common in patients with coronary artery disease.
- Revascularization aims to restore blood flow to the heart muscle.
- Assessing perfusion recovery post-revascularization is crucial for patient management.
Purpose of the Study:
- To analyze changes in myocardial perfusion recovery after revascularization.
- To evaluate the effectiveness of Dipyridamole-99mTc-Sestamibi SPECT in quantifying these changes.
- To compare outcomes between angioplasty and coronary artery bypass grafting (CABG).
Main Methods:
- 37 patients with wall motion abnormalities and myocardial infarction underwent Dipyridamole-99mTc-Sestamibi SPECT.
- Perfusion defects were assessed before and after revascularization (angioplasty or CABG).
- Bullseye parameters evaluated defect severity, size, and ischemia area compared to a normal database.
Main Results:
- Perfusion defects decreased by 31.4% in extension and 35.8% in severity.
- Ischemic areas were reduced by 75.7% post-revascularization.
- No significant differences in defect reduction were observed between angioplasty and CABG.
Conclusions:
- Revascularization achieved a moderate reduction in myocardial perfusion defects.
- A significant decrease in myocardial ischemia was observed post-revascularization.
- Dipyridamole-99mTc-Sestamibi SPECT effectively quantifies perfusion recovery after revascularization.
Unlabelled:
We analyzed the change in myocardial perfusion recovery after revascularization using Dipyridamole-99mTc-Sestamibi SPECT in 37 patients (mean age 59 years old; 33 males), all of whom had wall motion abnormalities and 84% who had myocardial infarction. The perfusion defects were evaluated before the revascularization and at 64 days of the angioplasty in 18 cases and of the coronary artery bypass graft (CABG) in 19 and were compared with a normal Dipyridamole database. The bullseye parameters were: decrease in severity, size and ischemia area of the defect and worsening of the defect. It was found that the defects decreased in an average of 31. 4% for extension and 35,8% for severity (with no significant differences between the 2 techniques); the ischemia was reduced in 75.7%. No new defects appeared although some presented a slight worsening. The net change in reduction was 26% for extension and 29% for severity.
Conclusion:
In patients with a high prevalence of myocardial infarction, revascularization obtained a moderate decrease in the perfusion defects and a significant ischemia decrease.